Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 5, 1998, Pages 751-756

  Wilson, Andrew M ^a   Brewster, Helen J A ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adrenal suppression; Asthma; Bone markers; Budesonide; Corticosteroids; Eosinophils; Triamcinolone acetonide

Indexed keywords

BUDESONIDE; TRIAMCINOLONE ACETONIDE;

ADRENAL SUPPRESSION; ADULT; ARTICLE; ASTHMA; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DRUG EFFICACY; EOSINOPHIL; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0031751656     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70014-4     Document Type: Article

References (30)

1. The British guidelines on asthma management. 1995 review and position statement. Thorax 1997;52(Suppl 1):S1-28.
2. National Asthma Education and Prevention Programme. Expert panel report II: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institute of Health; 1997. Publication No. 97-4051.
3. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol 1996;9:19-27.
4. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
5. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intra-nasal corticosteroids. Thorax 1997;52:476-82.
6. McIntyre HD, Mitchell CA, Bowler SD, Armstrong JG, Wooler JA, Cowley DM. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hr specimens. Thorax 1995;50:1280-4.
7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-43.
8. Johansson AS, Anderson FE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol 1982;22:523-9.
9. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from turbuhaler is twice that from a pressurised metered dose inhaler. Eur Respir J 1994;7:1839-44.
10. Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral and inhaled administration. J Clin Pharmacol 1995;35:302-5.
11. Toogood JH, Baskerville J, Jennings BA, Lefcoe NM, Johansson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989;84:688-700.
12. Wilson AM, Lipworth BJ. Systematic dose-response relationships with oral and inhaled corticosteroids in asthmatics. Thorax 1997;52(suppl 6):A57.
13. Iula A, Flynn CL, Deluccia F. Comparative study of the in vitro dose delivery and particle size distribution characteristics of an Azmacort metered-dose inhaler in combination with four different spacer devices. Cur Ther Res 1997;58:544-54.
14. Olsson B. Aerosol particle generation from dry powder inhalers: Can they equal pressurised meter dose inhalers? J Aerosol Med 1995;8(Suppl 3):S13-9.
15. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
16. Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 1992;4:161-7.
17. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996;42:697-705.
18. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davis P, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63(Suppl 122):86-95.
19. Heald D, Argenti D, Jensen B, Vaccaro S. The deposition of 14C triamcinolone acetonide administrated as single oral dose of 100μ.CI (800μg) to healthy volunteers. In: Proceedings of a joint meeting of the American Academy of Allergy, Asthma and Immunology and the American Thoracic Society in cooperation with the American College of Chest Physicians. Asthma 1995 Conference: Theory to Treatment; 1995 July 15-17; Chicago, Ill. p 14.
20. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997;52:55-8.
21. Wilson AM, McFarlane LC, Lipworth BJ. Dose response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med 1997;156:1274-7.
22. Aaronson D, Kaiser H, Dockhron R, Findlay S, Korenblat P, Thorsson L, et al. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose response study. J Allergy Clin Immunol 1998;101:312-9.
23. Grahnen A, Jansson B, Brundin RM, Ling-Anderssson A, Lonnebo A, Johansson M, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur J Clin Pharmacol 1997;52:261-7.
24. Lipworth BJ, Clark DJ. Effects of airway calibre on the lung delivery of nebulised salbutamol. Thorax 1997;52:47-9.
25. Brown PH, Blundell G, Greening AP, Crompton GK. Screening for hypothai mo-pituitary adrenal axis suppression in asthmatics taking high doses of inhaled corticesteroids. Respir Med 1991;85:511-6.
26. Broide J, Soferman R, Kivity S, Golander A, Dickstein G, Spirer Z, et al. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab 1995;80:1243-6.
27. Grebe SKG, Feek CM, Durham JA, Kljakovic M, Cooke RR. Inhaled beclomethasone dipropionate suppresses the hypothalamo-pituitary-adrenal axis in a dose dependant manner. Clin Endocrinol 1997;47:297-304.
28. Bootsma GP, Dekhuijzen PNR, Festen J, Mulder PGH, Vanherwaarden CLA. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measures of bronchial hyperresponsiveness in patients with stable asthma. Thorax 1995;50:1044-50.
29. Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiapparino A, Testi R. Once daily intranasal fluticasone propionate (200μg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98:274-82.
30. Knutsson U, Stiema P, Marcus C, Carlstedt-Duke J, Carlstrom K, Bronnegard M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 1995;144:301-10.